Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dimethyltryptamine,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I/ Phase II
Recipient : Entheon Biomedical
Deal Size : Inapplicable
Deal Type : Inapplicable
Entheon Biomedical Provides Update on Clinical and Preclinical DMT Programs
Details : Formulation and stability testing of DMT drug product by CHDR's partner pharmacy has commenced in accordance with projected start date of EBRX-101(N, N-dimethyltryptamine), a study that will evaluate controlled intravenous infusion of population of healt...
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 24, 2021
Lead Product(s) : Dimethyltryptamine,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I/ Phase II
Recipient : Entheon Biomedical
Deal Size : Inapplicable
Deal Type : Inapplicable
KEY PRODUCTS
Reset All
Laboratorium Ofichem, offering a flexible, high-tech environment to produce broad range of APIs for Human & Vet pharmaceutical markets.
